Meabco’s Drug Candidate Efficiently Mitigates Radiation-Induced Gastrointestinal Syndrome in MiceBy MeabcoIn News
BP-C2: Gastrointestinal Acute Radiation Syndrome Radiomitigative Potential in C57BL/6J Mouse ModelBy MeabcoIn News
Meabco Awarded a $5.9 Million US Government Contract to Advance its BP-C2 compound as a Medical Countermeasure for Cutaneous Radiation InjuriesBy MeabcoIn News